A phase II, open-label, multicenter study to evaluate the effect of tumor-based HER2 activation on the efficacy of rhuMAb 2C4 (pertuzumab) in subjects with advanced, refractory or recurrent ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Pertuzumab (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 31 Aug 2018 Biomarkers information updated
- 01 Jan 2008 Status changed from in progress to completed.
- 24 Sep 2005 New trial record.